Who is sponsoring NCT04966715?

NCT04966715 is sponsored by Jules Bordet Institute.

What drugs are being tested in NCT04966715?

Interventions in NCT04966715: Epigastric lymph node biopsy.

What condition does NCT04966715 study?

NCT04966715 studies Colorectal Carcinomatosis.

Is NCT04966715 still recruiting?

NCT04966715 is currently completed. Last updated 23 February 2024.

Last reviewed 2024-02-23 · How we verify

NCT04966715: EpiLyPath

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Inferior Epigastric Lymph Node in Colorectal Carcinosis

Completed NA Last updated 23 February 2024

What this trial tests

NA trial testing Epigastric lymph node biopsy in Colorectal Carcinomatosis in 20 participants. Completed in 31 January 2024.

Timeline

3 February 2022

Primary endpoint
31 December 2023

31 January 2024

Quick facts

Lead sponsor	Jules Bordet Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	20
Start date	3 February 2022
Primary completion	31 December 2023
Estimated completion	31 January 2024
Sites	1 location across Belgium

Drugs / interventions tested

Epigastric lymph node biopsy

Conditions studied

Colorectal Carcinomatosis — all drugs for Colorectal Carcinomatosis →

Sponsor

Jules Bordet Institute

Who can join

Adults 18 to 99, any sex, with Colorectal Carcinomatosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, the investigators propose to systematically collect and analyse epigastric lymph nodes during complete cytureductive surgery in patients with colorectal carcinomatosis, in order to define their role in the dissemination of colorectal metastases

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

14<sup>th</sup> PSOGI-ISSPP International congress on Peritoneal Surface Malignancies*: Lyon, 26 - 28<sup>TH</sup> September 2024.
· 2024 · PMID 39944920 · DOI 10.1515/pp-2024-0031

Verify or expand the search:

Other Jules Bordet Institute trials

Trials by the same sponsor.

NCT07455331 — Flash Radiotherapy for Skin Cancer · Phase 2 · not yet recruiting
NCT07431346 — Prophylactic Intervention for Dysgeusia in Head and Neck Cancer Patients Following Radio(Chemo)Therapy · NA · not yet recruiting
NCT06925984 — Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro- · NA · recruiting
NCT06523634 — Salvage Stereotactic Body Radiotherapy of the Prostate Bed for Biochemical Recurrence After Radical Prostatectomy. · NA · recruiting
NCT06227338 — ICG-fluorescence Imaging for Intraoperative Breast Cancer Margins Evaluation: a Dose-timing Study · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04966715 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jules Bordet Institute
Last refreshed: 23 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04966715.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing